Potashman, Michele http://orcid.org/0000-0001-7389-3354
Popoff, Evan http://orcid.org/0000-0002-3233-3147
Powell, Lauren
Mackenzie, Ainsley
Beiner, Melissa Wolfe
Coric, Vlad
Schmahmann, Jeremy http://orcid.org/0000-0003-0706-5125
L’Italien, Gilbert
Funding for this research was provided by:
Biohaven Pharmaceuticals, Inc
Article History
Accepted: 27 May 2024
First Online: 12 June 2024
Declarations
:
: Study 206 (BHV4157-206; NCT03701399) was a multisite study approved by a centralized independent Institutional Review Board (IRB; Advarra, Columbia, MD, USA) with additional local IRB approvals obtained where requested (per institute). The PROM-Ataxia study (MGH psychometric cohort) was approved by Mass General Brigham IRB (Somerville, MA, USA).
: All patients provided written consent to participate in the study and were free to withdraw at any time.
: Michele Potashman, Ainsley Mackenzie, Melissa Wolfe Beiner, Vlad Coric, and Gilbert L’Italien are employees of Biohaven Pharmaceuticals, Inc; Evan Popoff and Lauren Powell are employees of Broadstreet HEOR, which received funds from Biohaven Pharmaceuticals, Inc, for this work; Jeremy Schmahmann declares no conflict of interests. He consults for Biohaven Pharmaceuticals and is site PI for Biohaven Pharmaceuticals clinical trials NCT03701399, NCT02960893, and NCT03952806; receives royalties from Oxford University Press, Elsevier, MacKeith Press, and Springer; and is the inventor of the Brief Ataxia Rating Scale, Cerebellar Cognitive Affective/Schmahmann Syndrome Scale, the Patient Reported Outcome Measure of Ataxia, and the Cerebellar Neuropsychiatry Rating Scale, which are licensed to the General Hospital Corporation.